This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mebeverine is an antispasmodic used for the symptomatic treatment of stomach pain and spasms associated with irritable bowel syndrome and other gastrointestinal illnesses.
- Generic Name
- Mebeverine
- DrugBank Accession Number
- DB12554
- Background
Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Mebeverine (DB12554)
- Weight
- Average: 429.557
Monoisotopic: 429.251523231 - Chemical Formula
- C25H35NO5
- Synonyms
- Mebeverina
- Mebeverine
- Mebeverinum
- External IDs
- BRN 2783282
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Abdominal pain Combination Product in combination with: Simethicone (DB09512) •••••••••••• •••••••• •••••• •••••• Used in combination for symptomatic treatment of Abdominal spasms Combination Product in combination with: Simethicone (DB09512) •••••••••••• •••••••• •••••• •••••• Used in combination for symptomatic treatment of Abnormal bowel movement such as constipation, diarrhea, abdominal pain Combination Product in combination with: Simethicone (DB09512) •••••••••••• •••••••• •••••• •••••• Symptomatic treatment of Irritable bowel syndrome (ibs) •••••••••••• ••••••• Used in combination for symptomatic treatment of Bowel discomfort Combination Product in combination with: Simethicone (DB09512) •••••••••••• •••••••• •••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine. Aclidinium The risk or severity of adverse effects can be increased when Mebeverine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine. Alfentanil The risk or severity of adverse effects can be increased when Mebeverine is combined with Alfentanil. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Mebeverine hydrochloride 15VZ5AL4JN 2753-45-9 PLGQWYOULXPJRE-UHFFFAOYSA-N - International/Other Brands
- Colofac / Duspatal / Duspatalin / Rudakol
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DUSPATALIN RETARD CAPSULE 200 mg Capsule 200 mg Oral ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED 1994-10-03 Not applicable Singapore 
MEBETIN TABLET 135 mg Tablet, sugar coated 135 mg Oral ZYFAS PHARMA PTE LTD 1998-09-07 Not applicable Singapore - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ARLUY DUO Mebeverine hydrochloride (200 mg) + Simethicone (300 mg) Capsule, liquid filled Oral CATALENT ARGENTINA. SOCIEDAD ANONIMA. INDUSTRIAL Y COMERCIAL 2018-07-06 Not applicable Colombia 
Categories
- ATC Codes
- A03AA04 — Mebeverine
- Drug Categories
- Agents Causing Muscle Toxicity
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Amines
- Anticholinergic Agents
- Autonomic Agents
- Central Nervous System Agents
- Drugs for Functional Gastrointestinal Disorders
- Ethylamines
- Muscarinic Antagonists
- Parasympatholytics
- Peripheral Nervous System Agents
- Synthetic Anticholinergics, Esters With Tertiary Amino Group
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as p-methoxybenzoic acids and derivatives. These are benzoic acids in which the hydrogen atom at position 4 of the benzene ring is replaced by a methoxy group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- P-methoxybenzoic acids and derivatives
- Alternative Parents
- M-methoxybenzoic acids and derivatives / Amphetamines and derivatives / Benzoic acid esters / Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines show 7 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid or derivatives / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative show 20 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7F80CC3NNV
- CAS number
- 3625-06-7
- InChI Key
- VYVKHNNGDFVQGA-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
- IUPAC Name
- 4-{ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butyl 3,4-dimethoxybenzoate
- SMILES
- CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 4031
- PubChem Substance
- 347828778
- ChemSpider
- 3891
- 29410
- ChEBI
- 91514
- ChEMBL
- CHEMBL282121
- Wikipedia
- Mebeverine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Bladder Cancer / Incontinence / Incontinence, Daytime Urinary / Incontinence, Nighttime Urinary / Oncology / Orthotopic Neobladder 1 4 Completed Treatment Diarrhoea Predominant Irritable Bowel Syndrome 1 4 Completed Treatment Irritable Bowel Syndrome (IBS) 1 3 Completed Treatment Functional Bowel Disorders 1 3 Recruiting Treatment Irritable Bowel Syndrome (IBS) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, liquid filled Oral Capsule Oral Capsule Oral 200.000 mg Capsule, extended release Oral Tablet, coated Oral 135 mg/1 Tablet, sugar coated Oral Tablet, coated Oral 100 mg Capsule, extended release Oral 200 mg Syrup Oral 10 mg/ml Suspension Oral 1.000 g Suspension Oral 1 g Tablet, coated Oral 135 mg Tablet, film coated Oral Tablet, delayed release Oral 200 mg Tablet, sugar coated Oral 135 mg Capsule, delayed release Oral 200 mg Tablet, film coated Oral 135 MG Tablet Oral 135 mg Capsule Oral 200 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0029 mg/mL ALOGPS logP 4.87 ALOGPS logP 4.89 Chemaxon logS -5.2 ALOGPS pKa (Strongest Basic) 10.31 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 57.23 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 123.54 m3·mol-1 Chemaxon Polarizability 49.66 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 206.61266 predictedDeepCCS 1.0 (2019) [M+H]+ 209.0218 predictedDeepCCS 1.0 (2019) [M+Na]+ 216.18297 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:50 / Updated at June 08, 2021 11:32